Neuropsychiatric
Neuropeptides and analogues studied across cognition, mood, pain, and neurological disorders.
Questions
What does the Neuropsychiatric category cover?
The sampled monographs include approved pain medicine ziconotide, Russian-registered Semax and Selank, the variably marketed porcine-brain hydrolysate Cerebrolysin, and preclinical peptidomimetic Dihexa. This navigation group spans very different identities, uses, and evidence levels.
Are all sampled Neuropsychiatric entries approved in the United States or EU?
No. Ziconotide has US and EU approvals for a specific severe-pain indication. Semax and Selank are registered in Russia but lack FDA and EMA approval. Cerebrolysin has no FDA or centralized EMA approval, and no approved Dihexa product was identified.
How does the evidence for Semax and Selank compare with ziconotide?
Ziconotide has regulator-reviewed evidence for its labeled severe-pain use. The Semax and Selank monographs describe predominantly Russian studies, modest sample sizes, and no large Western-standard multicenter trial or independent replication. Approval in one jurisdiction should not be presented as approval elsewhere.
Why is Cerebrolysin treated as an identity boundary case?
Cerebrolysin is a complex porcine-brain protein hydrolysate containing peptides and amino acids, not a substance with one defined sequence or active ingredient. Its local authorization and indications require national-register checks, and reviews of stroke outcomes have reached differing conclusions.
What is the decisive evidence limitation for Dihexa?
Dihexa has never been tested in a human clinical trial, and its foundational mechanism paper was retracted after a research-misconduct investigation. No FDA-approved or EMA-authorized product was identified. Research-market visibility therefore does not establish clinical efficacy, safety, or authorization.
Join the atlas. Get the evidence updates.
Receive concise notes when peptide evidence, status, or source records change.